Ehave Inc (CE) (EHVVF) 시세

Sadly, feel into Expert Market

Their 15c-211 was pulled and were delisted into Expert Market. They would need to get a market maker to file a new 15c-211, but odds of that are super low....not impossible, but very unlikely.

Once you go to Expert market it's like cross the event horizon of a black hole....for most part there is no coming back.

At least for now

It's intriguing to observe EHVVF's transition into a biotech technology company, particularly as they navigate the realm of healthcare data management and the vast landscape of medical data storage solutions. The convergence of healthcare data with drug clinical trials holds immense potential for innovation. The prospect of an FDA-approved drug treatment for depression indeed seems promising, and your insights about the potential market impact resonate strongly.

It's exciting to see the potential in the healthcare data market, but it's essential to focus on data security, especially in the healthcare sector, to safeguard sensitive information like medical record data storage. Addressing the rising concerns of ransomware attacks is crucial to ensure the privacy and safety of patient data, and I hope the exploration of data security in the report leads to effective solutions for the industry.

Wen indictments?

now do .0002?

Still shillin this scam?

Bull chit...ehave is total trash, period.

Absolutely, healthcare data security is an enormous market, especially with the rising concerns surrounding ransomware attacks targeting the healthcare sector. It's crucial for organizations to prioritize robust security measures to safeguard sensitive patient information. Exploring innovative solutions and investing in healthcare data security is essential to protect against these threats and ensure the integrity and privacy of healthcare data.

HelioDXs Lab

Our behavioral panel assists clinicians in monitoring patients with chronic conditions like:

Depression
Tension
Panic disorders
Sleep disorders
Schizophrenia
Alzheimer’s
Bipolar disorders

https://heliosdx.com/services/behavioral-toxicology-panel/

.0000

Ehvvf

Dog chit

.002 = $720k market cap

+25% on RSHN news

Developing gene testing kits for psychedelics and Alzheimer's, which I think it the bigger news.

Alzheimer's a bigger market and many people would want a test to know if they had gene BEFORE it onsets later in life. This way may be ways to avoid it with meds and lifestyle changes.

more fake agreements...

yay!

still total dog chit

$ehvvf

stop shilling dog chit

Alzheimer's gene testing!

EHVVF and RSHN to develop gene test for Alzheimer's.

In the future, both parties will explore gene markers for other cognitive disorders like Alzheimer's.

I'm sure many people would want to know if they were at risk for that terrible disease

NEWS!!!

https://finance.yahoo.com/news/rushnet-inc-announces-agreement-ehave-123000884.html

Rushnet, Inc Announces Agreement with Ehave for Mental Health Lab Testing

ALPHARETTA, GA / ACCESSWIRE / May 9, 2023 / RushNet, Inc (OTC PINK:RSHN), (the "Company") announces agreement with Ehave, Inc. (OTC Pink: EHVVF), announces agreement with Ehave, Inc. (OTC Pink: EHVVF), for laboratory testing in the psychedelic and mental health sectors.

The company announced that it has signed a Memorandum of Understanding (MOU) with Ehave, Inc., which is a digital therapeutics provider for the psychedelic sector and the mental health sector, for the development of laboratory testing solutions and healthcare data management for the mental and wellness sectors.

HeliosDX's Behavioral Toxicology Test provides enhanced visibility of patients' health, allowing for a quicker diagnosis and treatment. This panel aims to help patients improve their quality of life by managing chronic conditions in a steady manner.

Both companies have agreed to explore genetic testing for DNA biomarkers, as well as pre-screening mental surveys that will provide insight into the individual's potential risk of adverse reactions when using ketamine and other psychedelics to treat mental illness.

Genetics may play a major role in determining an individual's response to psychedelic assisted psychotherapy. The gene variant CYP2B6 affects the metabolism of ketamine in 10-20% of people who carry a specific CYP2B6. The HTR2A mutation, carried by approximately 20% of the population, can also affect how people respond to serotonin. Serotonin is the primary mechanism for action of serotonergic psychoactives like psilocybin.

In the future, both parties will explore gene markers for other cognitive disorders like Alzheimer's.

Wen indictments?

As expected TPIA deal CANCELED.

ehave shareholders eat dog chit again.

Total shocker, not!

TPIA seeing some buying come in

That S-4 filed in late summer should be nearly ready to become effective as usually takes like 5-6 months.

Once it does TPIA could quickly shoot up towards $1.00 within minutes so maybe someone inside knows it's getting close

https://www.otcmarkets.com/stock/tpia/overview

Using NFTs to sell health data

Users would be able to convert their health data into NFTs then sell them to clinical trials for $$$$$

Nope. Still dog chit.

Dilution.

Tax loss buyers will start today

Anyone that wanted to sell in market for tax loss as already done so. After Jan 1st you get those buyers come back in to select issues, and today you get traders who try to get ahead of that by buying in on last trading day of year.

Ehave now part IBM Partner program

@Ehaveinc1
Excited to be accepted in #IBM PartnerWorld to build more tech for the healthcare industry.

https://twitter.com/Ehaveinc1/status/1605958890117468161

EHVVF healthcare cloud platform

Ehave $EHVVF MetaHealthU to develop healthcare cloud platform to offer ID verification, compliance, and data analytics for wearable devices and rural hospitals.

https://twitter.com/aiventuretech/status/1605242069525610503

Depends how many suckered they can find to dump freshly printed shares.

Never-ending dilution

30m OS to 350m OS...less than one year

Who wants some more of this dog chit?

Take the Never-ending 007s

P&D in progress.
Dilution event.
Never-ending 007s
Dog chit

Dilution

3 mill shares traded, Next stop .01+ !!!

2.3m shares traded so far

....could we do 3 mill, maybe even 4 mill+ shares today?

P&D central.

Pumptards shilling.

Healthcare data + drug clinical trial

EHVVF has become more a biotech technology company

Healthcare data management is huge business in healthcare industry; patient data, records, etc

Now include drug treatment for depression with FDA

This could easily make run to .05+ if not .10 like you said

Breaking out above 200-day resistance

Huge, we break above 200-day trend line and this could start to run FAST!

Could see FDA studies with TPIA also

4-week clinical trial sets stage for EHVVF to rocket once it breaks .0073 here

FDA approves IND application

Depression huge issue....this heading to .10+

This is BIG TIME! This is what I like to see talking MAJOR bullish here sweet!

Lol, w/ what money?

More dilution.

30m OS to 350m OS in under 1 year

Right after another RS

Dog chit.

NEWS: FDA approves Ehave study on depression!!!

https://finance.yahoo.com/news/fda-grants-ehave-consent-proceed-130000072.html

FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder

MIAMI, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, announced today that it received confirmation from the U.S. Food and Drug Administration ("FDA") that its review of Ehave's Investigational New Drug ("IND") application is complete. The FDA authorized Ehave to proceed with its clinical study, "An open label study of electrographic responses pre, during and post, a low dose, weekly intravenous ketamine infusion for 4 weeks, in a study population with major depression disorder (MDD)," submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ketamine HCl. The objective of this study is to characterize the change in EEG response of patients with MDD, during and 4 weeks after a course of IV ketamine infusions.

The clinical study includes 35 participants with Major Depression Disorder. It will include subjects with an inadequate response to at least two FDA-approved antidepressant therapies, including the current course of antidepressant therapy, at a sufficient dose and duration for the current episode. An electroencephalography machine measures the brain’s activity at baseline and after four weekly low-dose IV ketamine study treatments. The purpose of the study is to learn about the neurological responses seen on EEGs of participants receiving low-dose IV ketamine therapy. Dr. Jeffrey Kamlet and Tristar Wellness will complete the study. Dr. Kamlet has served as the principal investigator on more than 20 major pharmaceutical trials.

More than 264 million people across the globe suffer from depression. As a pervasive and often chronic health condition, depression is a global health burden and a significant source of disability. While depression might be considered a non-fatal health burden, severe depressive symptoms can lead to suicide, which is the second most common cause of death in people aged 15-29 years. Common treatments for depression include pharmacological interventions such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and tricyclic antidepressants (TCAs) and psychotherapy; however, the efficacy of these interventions often fails in severe cases.

Ketamine is a dissociative anesthetic, used most frequently in veterinary medicine and pediatrics, that has been repurposed as an off-label analgesic and antidepressant. Extensive investigation of its rapid antidepressive effects have been a breakthrough offering a potential reprieve to those suffering from MDD. Ketamine has also been shown to reduce suicidal ideation in depressed patients at risk for suicide. Similarly, the administration of ketamine was effective at reducing depressive symptoms, acute suicidal behavior, and mood lability in the youth with treatment-resistant depression (TRD) and bipolar disease. Intranasal esketamine is the only form of ketamine that has been FDA-approved as a treatment for TRD. However, clinical research and real-world feasibility have established significant drawbacks to intranasal ketamine, including patient discomfort with administration, greater risk of diversion to the illicit market, and potentially serious adverse reactions. Intravenous use of racemic ketamine is the more established route of administration as it has long been used as an anesthetic at much higher doses. Ehave management believes intravenous administration of ketamine includes benefits which include greater dose control and reduced cost of drug acquisition. This belief is the fundamental premise that has led to many dedicated outpatient clinics offering intravenous ketamine therapy for MDD across the United States.

"The upcoming clinical study for intravenous ketamine infusion in patients with treatment refractory major depressive disorder represents a significant milestone for Ehave's clinical programs," commented Ben Kaplan, CEO of Ehave. "There are many common pharmacological treatments for major depression disorder; however, the efficacy of these drugs often fails in severe cases. Intravenously administered ketamine may offer the potential for the remission of the symptoms in patients with MDD; however, it has not yet been approved by FDA for this purpose. This study will use an electroencephalography machine to measure the brain's activity and response while the intravenous ketamine is being delivered."

Dr. Ali from the Medical Advisory board says, “Studying the effects of IV ketamine by observing changes in brain activity on EEG is an important step in furthering Ehave’s mission. This approach can help advance the identification of potential biomarkers, which could one day be used to identify the specific patients who will respond best to ketamine intervention upfront, allowing the recommendation to made sooner in the course of illness and decreasing the amount of trial and error with treatment options.”

About Ehave, Inc.

Ehave is a leading healthcare services and technology company focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address many mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave’s operations span the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.

Stop shilling p&d dog chit

Volume picking up again

Starting to trade above 1mill shares per day, and even closer to 2mill

stop shilling this dog chit


$ehvvf - Ludlow was compensated three thousand six hundred dollars for research report, and holds business relationships through affiliate company, and thus should be considered a conflict of interest when reviewing this information.

https://ludlowresearch.com/ehvvf-bullish-outlook-mental-health-crisis/

$ehvvf - Ludlow was compensated three thousand six hundred dollars for research report, and holds business relationships through affiliate company, and thus should be considered a conflict of interest when reviewing this information.

https://ludlowresearch.com/ehvvf-bullish-outlook-mental-health-crisis/

Of course, it's a total shill.

Looking to dump shares on anyone willing to eat dog chit.

30M shares outstanding to 350M shares outstanding in less than a year.

Stop shilling this dog chit.

Nothing but a P & D.

This pos has wiped out everyone 3 separate times since 2018.

Stop shilling dog chit.

News this weekend

#Ehave $EHVVF will be conducting an interview this weekend with AI Venturetech to discuss our technology and potential use cases for healthcare data analytics in the mental health & wellness industry

https://twitter.com/Ehaveinc1/status/1601305811346661380

Healthcare data huge market

...and sounds bit like they will be exploring data security for healthcare sector, which needed from all ransomware attacks

Ehave price valuation targeted at .04. This is good! We all know the healthcare industry is worth BILLIONS. Smart move to get in. See link

https://ludlowresearch.com/ehvvf-bullish-outlook-mental-health-crisis/

Volume picking up!

This could be primed for run back above .01+

Launching product roadmap

#Ehave $EHVVF is launching a product #roadmap to #decentralized #health #data for #precision #health

https://twitter.com/Ehaveinc1/status/1600860312986652676

Too Bad it started a selling frenzy at the EOD...

Yes, saw this. It looks like there will be some HUGE developments coming.

I'm going to jump in for more myself.